Shilpa Biologicals Secures Exclusive Latin America Biosimilar Deal

's subsidiary, Shilpa Biologicals, has entered a strategic licensing agreement with SteinCares, a specialty healthcare firm in Latin America. This pact grants SteinCares exclusive rights to register, commercialize, and distribute an undisclosed biosimilar across the region. Shilpa Biologicals will handle product development and long-term manufacturing at its Dharwad, India facility.​ The collaboration leverages Shilpa's biologics expertise and SteinCares' regional strengths in regulatory navigation and market access. It positions both firms to address unmet needs in Latin American healthcare through affordable biosimilar alternatives. No specific financial terms or product details were disclosed in announcements. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.